News | November 28, 2024
Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
e brings over 27+ years of rich pharmaceutical experience
The inspection was a cGMP Inspection and had ended with NIL observations
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The drug will be manufactured at the group’s topical facility at Ahmedabad
Zydus unveils its ‘innovation and care’ centric corporate brand identity
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
Subscribe To Our Newsletter & Stay Updated
